MADRID, Spain – Enthusiasm among oncologists Monday following positive results from two phase III late-stage melanoma trials – one for an immunotherapy, the other for a combination targeted therapy – suggested Opdivo (nivolumab) and Tafinlar (dabrafenib) may soon replace interferon in Europe and Yervoy (ipilimumab) in the U.S. at the adjuvant setting.